Neujahrsbonus 2026: Dein Geschenk zum neuen Jahr

Eröffne Dein Depot bei unserem Broker finanzen.net ZERO und sicher Dir mit dem Code 'WINTER2025' 1 Gratis-Aktie, 1 ETF-Anteil und bis zu 300 € Wechselprämie!
Es gelten die Aktionsfristen und Teilnahmebedingungen.

Nicht mehr anzeigen

Johnson Johnson Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

174,38 EUR +0,26 EUR +0,15 %

15:03:49

STU

204,13 USD -3,21 USD -1,55 %

vorbörslich15:01:08

BTT

Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.425,71 Mrd. EUR

KGV24,98Div. Rendite3,40%

WKN853260

ISINUS4781601046

SymbolJNJ

Johnson Johnson Aktien News

Sortieren:Datum Meistgelesen

14:05EN, Johnson & JohnsonJohnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

14:03PR NewswireJohnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

29.12.25EN, Johnson & JohnsonJohnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

WerbungJohnson Johnson-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

22.12.25EN, Johnson & JohnsonEuropean Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

19.12.25EN, Johnson & JohnsonJohnson & Johnson Backs HRS Registry to Advance Real-World Evidence in PFA

18.12.25EN, Johnson & JohnsonJohnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

18.12.25PR NewswireJohnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

18.12.25PR NewswireU.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (la...

13.12.25EN, Johnson & JohnsonU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

13.12.25PR NewswireU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

09.12.25PR NewswireUnprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multip...

06.12.25EN, Johnson & JohnsonEarlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

06.12.25PR NewswireEarlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.